The U.S. Food and Drug Administration has approved daraxonrasib, a daily oral pill for patients with advanced metastatic pancreatic cancer.
This approval marks a significant shift in treating one of the deadliest forms of cancer, which kills about 50,000 Americans each year [1]. For patients with advanced metastatic disease, options have historically been limited and outcomes poor.
Daraxonrasib works by blocking RAS proteins, which are often mutated in pancreatic tumors. In a Phase III trial, the drug showed a median overall survival of 13.2 months [2]. In comparison, patients receiving standard chemotherapy had a median overall survival of 6.7 months [2].
This result represents an approximately two-fold increase in survival time [3]. The drug is administered as a once-daily pill, offering a different delivery method than traditional intravenous chemotherapy.
Trial data for the drug was presented at the ASCO 2026 annual meeting, though some reports indicate initial data was released in 2024. The FDA approval follows these findings that the medication could double survival time for specific patient populations [4].
Pancreatic cancer is often difficult to treat because it is frequently diagnosed at an advanced stage. The ability to extend life by several months provides a critical window for patients to spend more time with family, or explore other supportive care options.
“The drug showed a median overall survival of 13.2 months [2].”
The approval of daraxonrasib signals a move toward precision medicine in oncology by targeting specific RAS protein mutations. While a median survival of 13.2 months does not represent a cure, doubling the survival window compared to chemotherapy provides a substantial clinical improvement in a disease where survival gains are typically measured in weeks rather than months.
